Hepatitis C virus is a blood-borne virus that infects liver cells, resulting in illness that ranges from mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes, and others to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. Hepatitis C virus is transmitted through needlestick injuries, organ transplant from a carrier, and sexually or from infected mother to fetus.
Globally, hepatitis C virus exists in six distinct forms based on its genotypes, amongst which Type 1 is the most common form representing around 60-70% of global infections. Hepatitis C is diagnosed by blood tests for estimating viral load and genotyping, and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs, which inhibits protease or polymerase enzyme of virus is one of the treatments available for infection caused due to hepatitis C. Currently, no vaccines are available for the prevention of hepatitis C virus and this provides scope for the market players to expand their company portfolio.
Market Dynamics
Increasing prevalence of hepatitis C is expected to drive growth of hepatitis C drugs market over the forecast period. For instance, in 2018, according to the Centers for Disease Control and Prevention (CDC), around 3.9 million of U.S. population suffered from hepatitis C. Hepatitis C virus (HCV) infection is a commonly found blood borne infection in the U.S.
Moreover, in Canada, 246,000 number of Canada population suffered with HCV disease in 2017, wherein around 44% were unaware about HCV infection.
However, high cost of hepatitis C treatment is expected to hamper growth of the hepatitis C drugs market during the forecast period. For instance, in the U.S., a 12-week course of Sovaldi costs around US$ 84,000, where one pill costs around US$ 1,000. Similarly, Olysio drug costs around US$ 23,600 per month of hepatitis C treatment and treatment period for this drug was around 24-48 weeks.
Key features of the study:
- This report provides in-depth analysis of the global hepatitis C drugs market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2019-2027, considering 2018 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global hepatitis C drugs market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Abbvie Inc., Gilead sciences, Inc., BRISTOL-MYERS Squibb Company., F Hoffmann-la Roche Ltd, Merck & co., Inc., Johnson & Johnson, Natco Pharma Limited, and Kadmon holdings, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological upgradation, market expansion, and marketing tactics
- The global hepatitis C drugs market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for global hepatitis C drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
- Global Hepatitis C drugs Market, by Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- Global Hepatitis C drugs Market, by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hepatitis C drugs Market, by Region:
- North America
- By Country:
- By Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Type:
- Interferon Based Therapies
- NS5A Inhibitors
- NS5B Inhibitors
- Protease Inhibitors
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Abbvie Inc *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Gilead sciences, Inc.
- BRISTOL-MYERS Squibb Company.
- F Hoffmann-la Roche Ltd
- Merck & co., Inc.
- Johnson & Johnson
- Natco Pharma Limited
- Kadmon holdings, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
Table of Content - Hepatitis C Drugs Market
